MAP4K1 expression is a novel resistance mechanism and independent prognostic marker in AML-but can be overcome via targeted inhibition

• Tristan E. Knight,
• Holly Edwards,
• Jeffrey W. Taub,
• Yubin Ge

Affiliations

Tristan E. Knight

Division of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children (SickKids) and The University of Toronto, Toronto, Ontario, Canada

Holly Edwards

Department of Oncology, Wayne State University School of Medicine, 421 East Canfield, Detroit, MI 48201, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA

Jeffrey W. Taub

Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA; Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Children's Hospital of Michigan, Detroit, MI, USA

Yubin Ge

Department of Oncology, Wayne State University School of Medicine, 421 East Canfield, Detroit, MI 48201, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA; Corresponding author at: Department of Oncology, Wayne State University School of Medicine, 421 East Canfield, Detroit, MI 48201, USA.